Interpace Biosciences

For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.

For the three months ended Dec. 31, 2019, the firm's revenues fell to $4.1 million from $5.8 million in 2018, widely missing the analysts' average estimate of $10.8 million.

The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.

As part of the collaboration, UNC will use the firm's BarreGen assay to target molecular changes to predict resistance or relapse following ablation.

The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.

Cancer Genetics announced its planned merger with NovellusDx in September 2018, but scuttled the deal with the Israeli company a few months later.

The firm said that the second tranche is part of the financing provided by Ampersand Capital for the $23.5 million acquisition of Cancer Genetics' biopharma business earlier this year.

When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.

Interpace Diagnostics subsidiary Interpace BioPharma will perform services worldwide, while Genecast will offer the services in China.